Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305227 · ClinicalTrials.gov registry record · Phase 2
Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00305227 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 100 participants.
The verdict
NCT00305227, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Recurrent urinary tract infections (RUTIS) continue to be a major health problem in women and are now complicated by increasing antibiotic resistance. New preventive approaches are needed. Because most women with RUTI lack the normal protective Lactobacillus (LB) in their vaginal flora, we hypothesized that restoration of LB would reduce RUTIS. In this trail, women with recent UTI are randomized to receive either LB or placebo vaginal capsules and are followed for side effects, for colonization with LB and for occurrence of RUTI over hte next four months.
Interventions
- DRUG Placebo
- DRUG Lactin-V
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305227
The ClinicalTrials.gov registry entry for NCT00305227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00305227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305227 about?
NCT00305227 is a clinical study titled "Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection". Recurrent urinary tract infections (RUTIS) continue to be a major health problem in women and are now complicated by increasing antibiotic resistance. New preventive approaches are needed. Because most women with RUTI lack the normal protective Lactobacillus (LB) in their vaginal flora, we hypothesi...
What is the current status of trial NCT00305227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2006-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00305227?
The interventions under investigation include: Placebo (DRUG), Lactin-V (DRUG).
Who is sponsoring clinical trial NCT00305227?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.